

P&T Motion History ADHD

Drugs reviewed	Motion	Date reviewed	Scan accepted as adequate update	Reiteration of prior motion	Decision
<u>Amphetamines:</u> amphetamine dextroamphetamine lisdexamfetamine methamphetamine mixed amphetamine salts <u>Methylphenidates:</u> dexmethylphenidate methylphenidate transdermal film methylphenidate <u>Other Stimulants:</u> armodafinil* modafinil* <u>Non-Stimulants:</u> atomoxetine clonidine guanfacine	<p>After considering the evidence of safety, efficacy and special populations for the treatment of Attention Deficit Hyperactivity Disorder (ADHD), I move that methylphenidate based and amphetamine based agents of both long and short acting formulations are safe and efficacious. A long and short acting formulation of each stimulant should be preferred drugs on the Washington State Preferred Drug List. No single stimulant medication is associated with fewer adverse events in special populations. The stimulants listed above shall not be subject to therapeutic interchange on the Washington Preferred Drug List.</p> <p>After considering the evidence of safety efficacy and special populations for the treatment of Attention Deficit Hyperactivity</p>	June 20, 2018	Yes Schwilke Park	Yes Buccola Sanderson	Passed unanimous

BOLD = new this update
 *(grey) = not part of PDL
 7/13/2011

P&T Motion History
ADHD

	<p>Disorder (ADHD), I move that the alpha agonists clonidine and guanfacine are safe and efficacious and that both of these agents should be included as a preferred drug on the Washington State Preferred Drug List.</p> <p>Motion: Figueroa 2nd: Schwilke</p>				
--	---	--	--	--	--